Premium
Novel food‐based delivery of microencapsulated omega‐3 fatty acids (μN3): Potential role in promoting cardiovascular health
Author(s) -
Earnest Conrad P,
David Robert M,
Bralley James A
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.5.a307-c
Subject(s) - meal , placebo , fish oil , food science , medicine , postprandial , ingestion , orange juice , cardiovascular health , zoology , fish <actinopterygii> , chemistry , endocrinology , diabetes mellitus , biology , disease , alternative medicine , pathology , fishery
The role of N3 in supporting cardiovascular health has been well established yet, many Americans are resistant to consuming fish or fish‐oil supplements. We examined the use of a new food technology where μN3 is delivered in common foods such as bread, yogurt, milk and orange juice. In a randomized‐double blind, placebo‐controlled, pilot trial, we assigned 20 subjects (Age 2.5 ± 6.2 y; wt. 73.4 ± 5.1 kg) to receive a breakfast meal using μN3 foods (~500 kcals) delivering ~1,000 mg (450–550 mg EPA/DHA) or a matching placebo meal for 14d. Primary outcomes included changes in plasma [EPA] and [DHA]. Secondary outcomes examined triglycerides (TG). After analyzing our data using a 2x2 ANCOVA covaried for age and BMI and Tukey‐Kramer post‐hoc test. We observed that the μN3 group showed significant mean (SE) elevations in plasma DHA (91.18 ± 9.3 vs. 125.58 ±11.3 u mol/L; P<0.05) and reduced in TG (89.89 ± 12.8 vs. 80.78 ± 10.4 mg/dL; P<0.05). When expressed as Δ scores DHA and TG were different from placebo (P<0.05). No other changes were observed though [EPA] demonstrated a tendency to increase in the μN3 group (P=0.08). Interestingly, the change in TG was significantly correlated with the change in EPA (r 2 = 0.33; P<0.04). Lastly, participants reported no taste, odor or “burp‐back” associated with μN3 food ingestion. The use of μN3 foods should be further explored using longer treatment periods and more robust cardiovascular endpoints as a means of delivering N3 to populations resistant to fish or supplement ingestion. Supported by Ocean Nutrition Canada